Refractory Hodgkin’s disease, also known as relapsed or refractory Hodgkin lymphoma, occurs when the cancer does not respond to treatment or comes back after a period of remission. While most people with Hodgkin lymphoma are cured with initial treatment, roughly one-quarter of patients face the challenge of disease that either never fully goes away or returns, requiring additional rounds of therapy and sometimes more intensive approaches.

Understanding Relapsed and Refractory Hodgkin Lymphoma

When doctors talk about Hodgkin lymphoma that has returned or persisted, they use two specific terms that describe different situations. The word relapsed refers to disease that comes back or starts growing again after a period when it seemed to be gone, which is called remission. On the other hand, the term refractory describes a situation where the lymphoma does not respond to treatment from the start, meaning the cancer cells continue to grow despite therapy, or when any response to treatment does not last very long.^[1]

For people with classical Hodgkin lymphoma, the timing of when disease returns follows certain patterns. Most relapses happen within the first three years after diagnosis, though some people experience the disease coming back much later than this. This means that even after several years of being well, ongoing monitoring remains important for anyone who has been treated for Hodgkin lymphoma.^[1]

The good news is that for patients who relapse or whose disease proves refractory, secondary therapies can often be successful. Many people achieve another remission with additional treatment, and some may even be cured of the disease despite it returning or not responding initially. However, the outlook varies from person to person based on several factors that influence treatment decisions.^[1]

How Common Is Refractory Hodgkin’s Disease

Approximately 25 percent of people diagnosed with Hodgkin lymphoma will experience either a relapse or have disease that is refractory to initial therapy. This means that while the overall cure rate for Hodgkin lymphoma is quite high, a significant minority of patients face additional challenges. The situation becomes particularly concerning for certain groups within this population.^[3]

The prognosis becomes especially difficult for patients whose disease is truly chemotherapy refractory, meaning they are unable to obtain even temporary disease control with standard treatments. Similarly, people who relapse after undergoing high-dose chemotherapy and autologous stem cell transplant (a procedure where a patient’s own stem cells are collected and given back after intensive chemotherapy) face particularly challenging circumstances.^[3]

Despite the cure rate in Hodgkin lymphoma already being high, research continues to search for better ways to treat the minority of patients who are refractory to treatment and those who experience relapse. This ongoing research effort recognizes that even though most patients do well, improving outcomes for everyone remains a critical goal.^[1]

What Influences Treatment Choices

When healthcare teams develop a treatment plan for someone with relapsed or refractory Hodgkin lymphoma, they consider numerous factors that make each patient’s situation unique. The timing of the relapse plays a crucial role in decision-making. Whether the disease came back within months of finishing treatment or several years later significantly affects which therapies might work best.^[1]

A patient’s age and overall health status are equally important considerations. Younger, otherwise healthy individuals may be candidates for more intensive treatment approaches, including high-dose chemotherapy followed by stem cell transplantation. In contrast, older adults or people with other health conditions may need different, less intensive treatment strategies that still offer benefit without overwhelming side effects.^[1]

The extent and location of disease at the time of relapse also matters greatly. Someone whose disease has returned to only one area of lymph nodes faces a different situation than someone with widespread disease throughout the body. Additionally, which treatments a person received during their initial therapy influences what options remain available, as doctors try to avoid using the same medications that did not work before or that might cause cumulative toxicity.^[1]

Negative Prognostic Factors

Certain characteristics at the time of relapse suggest a more challenging road ahead and help doctors assess risk and plan treatment accordingly. A remission duration of less than one year stands out as a particularly important negative sign. When disease comes back quickly after initial treatment, it often indicates more aggressive cancer that may be harder to control with subsequent therapies.^[3]

Having advanced stage disease or extranodal disease (cancer that has spread outside the lymph nodes to other organs) at the time of relapse also represents a less favorable situation. Similarly, the presence of B symptoms at relapse carries negative implications. B symptoms include fever of 38 degrees Celsius or higher, drenching and recurrent night sweats, and unexplained weight loss of 10 percent or more of baseline weight in the previous six months.^[3]

More recently, doctors have learned that results from imaging tests can predict outcomes. A negative PET scan (positron emission tomography scan, which looks for areas of high metabolic activity in the body) suggesting complete remission after treatment but before stem cell transplant has been identified as an important positive prognostic factor for patients in first relapse undergoing transplantation.^[3]

Standard Treatment Approaches

The current standard approach for most patients with relapsed or refractory Hodgkin lymphoma involves combination chemotherapy, usually followed by autologous stem cell transplantation. This strategy represents the established treatment path that has proven successful for many people. In some cases, involved site radiation therapy (radiation directed specifically at areas where cancer cells remain) may also be incorporated into the treatment plan.^[1]

Healthcare teams may choose from a variety of single-agent therapies or combination chemotherapy regimens. Several targeted medications have shown effectiveness, including brentuximab vedotin (Adcetris), bendamustine (Treanda), nivolumab (Opdivo), and pembrolizumab (Keytruda). These medications work through different mechanisms than traditional chemotherapy, often with different side effect profiles.^[1]

Multiple combination chemotherapy regimens remain important treatment options. These include DHAP (dexamethasone, cisplatin, and cytarabine), ESHAP (etoposide, methylprednisolone, cisplatin, and cytarabine), GVD (gemcitabine, vinorelbine, and liposomal doxorubicin), ICE (ifosfamide, carboplatin, and etoposide), and IGEV (ifosfamide, gemcitabine, and vinorelbine), among others. The choice among these regimens depends on individual patient factors and what treatments were used previously.^[1]

Stem Cell Transplantation

A stem cell transplant serves as the main treatment for Hodgkin lymphoma that does not completely disappear after treatment with chemotherapy or radiation therapy. It may also be offered if the lymphoma comes back soon after the original treatment is finished. The procedure involves using high-dose chemotherapy to kill all cells in the bone marrow, both cancerous and healthy, followed by the infusion of healthy stem cells to replace those that were destroyed.^[2]

Hodgkin lymphoma patients who fail to achieve complete remission following frontline therapy or who relapse after achieving complete remission are often treated with second-line chemotherapy regimens, followed by a bone marrow or stem cell transplant. The transplant of bone marrow or stem cells is needed to restore healthy bone marrow function, which is essential for producing blood cells.^[1]

In an autologous type of transplant, stem cells are taken from the patient’s own bone marrow or blood before intensive chemotherapy is given, then returned afterward. In an allogeneic type of transplant, stem cells are collected from another person, usually a closely matched donor. If Hodgkin lymphoma remains after an autologous stem cell transplant, an allogeneic stem cell transplant may be an option for some people, though this carries additional risks and complications.^[2]

Radiation Therapy for Relapsed Disease

For some patients with relapsed Hodgkin lymphoma, radiation therapy may be offered as part of the treatment plan, particularly if they have not previously received radiation. This approach works best when disease has returned or remains in only one lymph node area. Radiation therapy uses high-energy rays or particles to destroy cancer cells in specific locations.^[2]

Radiation may be given alone or combined with chemotherapy, depending on the individual situation. It may also be used as part of preparation for a stem cell transplant, helping to eliminate cancer cells before the transplant procedure. The decision to use radiation therapy depends on where the disease is located, what treatments were previously given, and the patient’s overall health status.^[2]

Targeted Therapy Options

Targeted therapy uses drugs to target specific molecules such as proteins on cancer cells or inside them. These treatments work by stopping the growth and spread of cancer while limiting harm to normal cells. This approach differs from traditional chemotherapy, which affects all rapidly dividing cells in the body. Targeted therapies may be offered for relapsed or refractory classical Hodgkin lymphoma if the disease remains or continues to grow after other treatments.^[2]

The development and approval of three highly active novel agents over the past decade has significantly changed the treatment landscape for relapsed and refractory Hodgkin lymphoma. Brentuximab vedotin, an anti-CD30 antibody-drug conjugate, along with the PD-1 inhibitors nivolumab and pembrolizumab, have substantially expanded options for salvage therapy prior to autologous transplantation, post-transplant maintenance, and treatment of relapse after transplant. These advances have led to improved survival in the modern era.^[10]

Treatments Under Investigation

Although the cure rate in Hodgkin lymphoma is already high, research continues to look for ways to treat patients whose disease proves difficult to control. Many promising therapies are currently being tested in clinical trials. These investigational treatments include anti-CD30-CAR T cells, atezolizumab (Tecentriq), bortezomib (Velcade), carfilzomib (Kyprolis), and everolimus (Afinitor).^[1]

Ongoing studies are also assessing biomarkers of response to immunotherapy and dynamic biomarkers such as circulating tumor DNA. These research efforts may further inform treatment decisions in the future and enable a more personalized approach to therapy. The goal is to identify which patients will benefit most from specific treatments, avoiding unnecessary side effects for those unlikely to respond.^[10]

Treatment Considerations for Older Adults

Managing relapsed or refractory Hodgkin lymphoma in older adults and transplant-ineligible patients requires a different approach than that used for younger, healthier individuals. Older adults may not tolerate intensive chemotherapy regimens well, and the risks of stem cell transplantation may outweigh potential benefits in this population. This represents a major challenge for management, as these patients need effective treatment options that do not overwhelm their system.^[3]

For these patients, less intensive regimens may be selected, focusing on controlling disease while maintaining quality of life. The availability of newer targeted therapies and immunotherapies has been particularly beneficial for this group, as these treatments often cause fewer severe side effects than traditional chemotherapy while still offering meaningful disease control.^[3]

Chemotherapy Selection Based on Previous Response

When selecting chemotherapy for relapsed disease, doctors consider how well the cancer responded to previous treatments. If Hodgkin lymphoma responded well to certain chemotherapy drugs the first time they were given, those same drugs might be used again. However, if the disease did not respond or came back quickly, different combinations will likely be chosen.^[2]

Multiple combination chemotherapy regimens are available for treating relapsed or refractory Hodgkin lymphoma. Options include GDP (gemcitabine, dexamethasone and cisplatin), DICEP (dexamethasone, cyclophosphamide, etoposide, cisplatin and mesna), and several others. The specific regimen selected depends on individual patient factors, previous treatments received, and treatment goals.^[2]

Living With Relapsed or Refractory Disease

Receiving news that Hodgkin lymphoma has relapsed or is refractory to treatment brings significant emotional challenges. Many people feel shocked, frightened, or angry when they learn the disease has returned or never fully went away. These feelings are completely normal and valid responses to difficult news. Support from healthcare teams, counselors, support groups, and loved ones becomes especially important during this time.^[14]

Follow-up care after treatment for relapsed disease typically involves appointments every few months at first, becoming less frequent over time as patients remain disease-free. Some hospitals now use supported self-management approaches for follow-up, where patients learn which symptoms to watch for and can contact their healthcare team if concerns arise, rather than having regularly scheduled appointments. Regular blood tests to check general health are usually performed at the patient’s general practitioner’s office.^[14]

After two to three years of monitoring, if patients remain well, their hospital may hand care back to their general practitioner. However, this does not mean surveillance stops completely. Patients should remain vigilant for any new symptoms and maintain open communication with their healthcare providers. After five years post-treatment, meeting with an oncologist at least once a year remains advisable to monitor recovery progress.^[14]

Long-Term Outlook and Survival

Most patients with classical Hodgkin lymphoma are cured with combination chemotherapy, but approximately 10 to 20 percent will relapse, and another 5 to 10 percent will have primary refractory disease. The treatment landscape has evolved significantly over the past decade, leading to improved cure rates and overall survival for patients with relapsed or refractory disease.^[10]

For patients who relapse or become refractory, secondary therapies are often successful in providing another remission and may even cure the disease. However, success rates vary depending on multiple factors including timing of relapse, extent of disease, previous treatments received, and individual patient characteristics. Working closely with experienced healthcare teams specializing in lymphoma provides the best opportunity for optimal outcomes.^[1]